« Previous
Next »
International Journal of Radiation Oncology * Biology * Physics
Volume 73, Issue 3
, Pages
897-903
, 1 March 2009
The Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor Cediranib (Recentin; AZD2171) Inhibits Endothelial Cell Function and Growth of Human Renal Tumor Xenografts
To access this article, please choose from the options below
Supported in part by a grant from AstraZeneca and US Public Health Service Grant CA089655 from the U.S. National Cancer Institute.
Conflict of interest: These studies were supported in part by a research grant to Dr. Siemann from AstraZeneca. Dr. Juliane Jürgensmeier is an employee of AstraZeneca.
PII: S0360-3016(08)03673-0
doi: 10.1016/j.ijrobp.2008.10.031
© 2009 Elsevier Inc. All rights reserved.
« Previous
Next »
International Journal of Radiation Oncology * Biology * Physics
Volume 73, Issue 3
, Pages
897-903
, 1 March 2009
